Bristol-Myers Squibb (BMY) Tops Q3 EPS by 11c; lifts outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $61.28 -0.65%
Revenue Growth %: +4.3%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +4.3%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.63, $0.11 better than the analyst estimate of $1.52. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.8 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2025 EPS of $6.40-$6.60, versus the consensus of $6.36. Bristol-Myers Squibb sees FY2025 revenue of $47.5-48 billion, versus the consensus of $47.34 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Putin's Aide Says War In Ukraine Moving Toward An End - Vesti
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Solaris Oilfield Infrastructure shares jump on Morgan Stanley upgrade
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
